Skip to Content

Semaglutide May Aid Weight Loss in Obese Patients With T2DM

FRIDAY, March 5, 2021 -- Semaglutide 2.4 mg is associated with superior and clinically meaningful weight loss compared with placebo for adults with overweight or obesity and type 2 diabetes, according to a study published online March 2 in The Lancet.

Melanie Davies, M.D., from the University of Leicester in the United Kingdom, and colleagues conducted a phase 3, superiority trial involving adults with a body mass index of ≥27 kg/m2 with type 2 diabetes. A total of 1,210 participants, recruited from 149 outpatient clinics in 12 countries were randomly assigned to a subcutaneous injection of semaglutide 2.4 mg (404 participants), semaglutide 1.0 mg (403 participants), or visually matching placebo (403 participants) once a week for 68 weeks, together with a lifestyle intervention.

The researchers found that from baseline to week 68, the estimated change in mean body weight was −9.6 percent with semaglutide 2.4 mg, −7.0 percent with semaglutide 1.0 mg, and −3.4 percent with placebo. At week 68, the percentage of patients who had achieved weight reductions of at least 5 percent was higher for those in the semaglutide 2.4 mg group versus placebo group (68.8 versus 28.5 percent; odds ratio, 4.88). Adverse events occurred more frequently with semaglutide 2.4 mg and 1.0 mg versus placebo (87.6 and 81.8 percent, respectively, versus 76.9 percent).

"These results are exciting and represent a new era in weight management in people with type 2 diabetes -- they mark a real paradigm shift in our ability to treat obesity, the results bring us closer to what we see with more invasive surgery," Davies said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM

MONDAY, April 16, 2021 -- There are racial/ethnic, gender, and socioeconomic disparities apparent in access to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment for...

Gens X and Y Show Worrisome Trend of Declining Health

FRIDAY, April 16, 2021 -- Gen X and Gen Y are showing poorer physical health and higher levels of unhealthy behaviors compared with older generations, according to a study...

Excess Body Weight Tied to Higher Health Costs Across BMI Levels

WEDNESDAY, April 14, 2021 -- Excess body weight is associated with higher health care costs across body mass index (BMI) levels, according to a study published online March 24 in...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.